Turrentine Mark A, Ramirez Mildred M, Mastrobattista Joan M
Department of Obstetrics, Gynecology and Reproductive Sciences, Kelsey Research Foundation, University of Texas Medical School, Houston, TX 77007, USA.
Infect Dis Obstet Gynecol. 2009;2009:934698. doi: 10.1155/2009/934698. Epub 2009 Dec 13.
To estimate the costs and outcomes of rescreening for group B streptococci (GBS) compared to universal treatment of term women with history of GBS colonization in a previous pregnancy.
A decision analysis model was used to compare costs and outcomes. Total cost included the costs of screening, intrapartum antibiotic prophylaxis (IAP), treatment for maternal anaphylaxis and death, evaluation of well infants whose mothers received IAP, and total costs for treatment of term neonatal early onset GBS sepsis.
When compared to screening and treating, universal treatment results in more women treated per GBS case prevented (155 versus 67) and prevents more cases of early onset GBS (1732 versus 1700) and neonatal deaths (52 versus 51) at a lower cost per case prevented ($8,805 versus $12,710).
Universal treatment of term pregnancies with a history of previous GBS colonization is more cost-effective than the strategy of screening and treating based on positive culture results.
评估与对既往妊娠有B族链球菌（GBS）定植史的足月孕妇进行普遍治疗相比，重新筛查GBS的成本和结果。
采用决策分析模型比较成本和结果。总成本包括筛查成本、产时抗生素预防（IAP）成本、母体过敏反应和死亡的治疗成本、母亲接受IAP的健康婴儿的评估成本以及足月新生儿早发性GBS败血症的治疗总成本。
与筛查和治疗相比，普遍治疗每预防一例GBS病例所治疗的女性更多（155例对67例），并以更低的每例预防成本（8805美元对12710美元）预防更多早发性GBS病例（1732例对1700例）和新生儿死亡（52例对51例）。
对既往有GBS定植史的足月妊娠进行普遍治疗比基于阳性培养结果进行筛查和治疗的策略更具成本效益。
